{"title":"基于模型的全身麻醉患者雷马唑仑精确给药。","authors":"Yueting Chen, Zuo-Jing Zhang, Xiao-Feng Zhang, Yuan Peng, Zheng Jiao, Jing-Xiang Wu","doi":"10.2147/DDDT.S495604","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to characterize the pharmacokinetics/pharmacodynamics (PK/PD) of remimazolam in patients under general anesthesia using a population analysis and to develop a web-based dashboard tool that directly displays the optimal dosing regimen for general anesthesia.</p><p><strong>Patients and methods: </strong>A total of 20 patients received remimazolam for general anesthesia, during which intensive arterial blood samples and bispectral index (BIS) values were collected. A population PK/PD model was established, and goodness-of-fit and visual predictive check plots were utilized to evaluate the model's accuracy. Additionally, RxODE and Shiny in R were used to design a web-based dashboard tool to recommend optimal dosing regimens.</p><p><strong>Results: </strong>The three-compartment model with first elimination best described the PK profiles of remimazolam. PK parameters were weight-adjusted via allometric scaling. The correlation between drug exposure and the BIS was optimally characterized through an effect compartment model employing an inhibitory sigmoid Emax model. In addition, a web-based dashboard tool was created to offer initial personalized dosing strategies for general anesthesia procedures, enhanced by graphical representations of the PK/PD profiles associated with the recommended dosing regimens.</p><p><strong>Conclusion: </strong>The developed population PK/PD model effectively captured the dose-exposure-response relationship for remimazolam, allowing for the optimization of personalized dosing strategies.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"5099-5109"},"PeriodicalIF":4.7000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180593/pdf/","citationCount":"0","resultStr":"{\"title\":\"Model-Informed Precision Dosing of Remimazolam in General Anesthesia Patients.\",\"authors\":\"Yueting Chen, Zuo-Jing Zhang, Xiao-Feng Zhang, Yuan Peng, Zheng Jiao, Jing-Xiang Wu\",\"doi\":\"10.2147/DDDT.S495604\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study aimed to characterize the pharmacokinetics/pharmacodynamics (PK/PD) of remimazolam in patients under general anesthesia using a population analysis and to develop a web-based dashboard tool that directly displays the optimal dosing regimen for general anesthesia.</p><p><strong>Patients and methods: </strong>A total of 20 patients received remimazolam for general anesthesia, during which intensive arterial blood samples and bispectral index (BIS) values were collected. A population PK/PD model was established, and goodness-of-fit and visual predictive check plots were utilized to evaluate the model's accuracy. Additionally, RxODE and Shiny in R were used to design a web-based dashboard tool to recommend optimal dosing regimens.</p><p><strong>Results: </strong>The three-compartment model with first elimination best described the PK profiles of remimazolam. PK parameters were weight-adjusted via allometric scaling. The correlation between drug exposure and the BIS was optimally characterized through an effect compartment model employing an inhibitory sigmoid Emax model. In addition, a web-based dashboard tool was created to offer initial personalized dosing strategies for general anesthesia procedures, enhanced by graphical representations of the PK/PD profiles associated with the recommended dosing regimens.</p><p><strong>Conclusion: </strong>The developed population PK/PD model effectively captured the dose-exposure-response relationship for remimazolam, allowing for the optimization of personalized dosing strategies.</p>\",\"PeriodicalId\":11290,\"journal\":{\"name\":\"Drug Design, Development and Therapy\",\"volume\":\"19 \",\"pages\":\"5099-5109\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-06-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180593/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Design, Development and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/DDDT.S495604\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S495604","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
摘要
目的:本研究旨在通过人群分析来表征全身麻醉患者雷马唑仑的药代动力学/药效学(PK/PD),并开发一个基于网络的仪表板工具,直接显示全身麻醉的最佳给药方案。患者和方法:共20例患者接受雷马唑仑全麻,麻醉期间采集强化动脉血及双谱指数(BIS)值。建立了种群PK/PD模型,利用拟合优度和视觉预测检验图对模型的准确性进行了评价。此外,RxODE和Shiny in R被用于设计一个基于网络的仪表板工具,以推荐最佳给药方案。结果:第一消除三室模型最能描述雷马唑仑的PK谱。通过异速缩放法调整PK参数的权重。药物暴露与BIS之间的相关性通过采用抑制乙状结肠Emax模型的效应室模型得到了最佳表征。此外,还创建了一个基于网络的仪表板工具,用于提供全身麻醉过程的初始个性化给药策略,并通过与推荐给药方案相关的PK/PD概况的图形表示来增强。结论:建立的人群PK/PD模型有效捕捉了雷马唑仑的剂量-暴露-反应关系,可优化个体化给药策略。
Model-Informed Precision Dosing of Remimazolam in General Anesthesia Patients.
Purpose: This study aimed to characterize the pharmacokinetics/pharmacodynamics (PK/PD) of remimazolam in patients under general anesthesia using a population analysis and to develop a web-based dashboard tool that directly displays the optimal dosing regimen for general anesthesia.
Patients and methods: A total of 20 patients received remimazolam for general anesthesia, during which intensive arterial blood samples and bispectral index (BIS) values were collected. A population PK/PD model was established, and goodness-of-fit and visual predictive check plots were utilized to evaluate the model's accuracy. Additionally, RxODE and Shiny in R were used to design a web-based dashboard tool to recommend optimal dosing regimens.
Results: The three-compartment model with first elimination best described the PK profiles of remimazolam. PK parameters were weight-adjusted via allometric scaling. The correlation between drug exposure and the BIS was optimally characterized through an effect compartment model employing an inhibitory sigmoid Emax model. In addition, a web-based dashboard tool was created to offer initial personalized dosing strategies for general anesthesia procedures, enhanced by graphical representations of the PK/PD profiles associated with the recommended dosing regimens.
Conclusion: The developed population PK/PD model effectively captured the dose-exposure-response relationship for remimazolam, allowing for the optimization of personalized dosing strategies.
期刊介绍:
Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications.
The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas.
Specific topics covered by the journal include:
Drug target identification and validation
Phenotypic screening and target deconvolution
Biochemical analyses of drug targets and their pathways
New methods or relevant applications in molecular/drug design and computer-aided drug discovery*
Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes)
Structural or molecular biological studies elucidating molecular recognition processes
Fragment-based drug discovery
Pharmaceutical/red biotechnology
Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products**
Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development
Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing)
Preclinical development studies
Translational animal models
Mechanisms of action and signalling pathways
Toxicology
Gene therapy, cell therapy and immunotherapy
Personalized medicine and pharmacogenomics
Clinical drug evaluation
Patient safety and sustained use of medicines.